- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Meet the Board: Don Hall of DeltaSigma Talks Effects COVID has on Fee-for-Service, Value-Based Care, Health Disparities and More
In this episode of Tuning Into the C-Suite, listeners are tuning into our next feature of the Meet the Board series where MHE's Senior Editor, Peter Wehrwein, and Associate Editor, Briana Contreras, speak with Managed Healthcare Executive Editorial Advisory Board Member, Don Hall, who is principal of DeltaSigma LLC. DeltaSigma is a consulting practice specializing in strategic problem solving for managed care organizations. In addition to being a loyal member of our board since 2007, Don most recently served as president and CEO of a nonprofit, provider-sponsored health plan. In this conversation, you’ll learn a bit about Don, personally, such as what he's currently reading, and his thoughts about the current issues healthcare is facing today.
To listen to more episodes featured on Tuning Into The C-Suite, visit us on Spotify, Apple Podcasts and iHeartRadio.
Don Hall
Medicare Patients with PAH Face High Out-of-Pocket Costs | 2024 ATS
May 19th 2024Medicare patients who have pulmonary arterial hypertension and who are eligible for the low-income subsidy often have advanced disease, require prolonged disability insurance and face financial hardships, according to a poster at the annual ATS meeting.
Read More
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Dr. Glaucomflecken the Opening Speaker Today at the 2024 ATS Meeting | 2024 ATS
May 18th 2024William Flanary, M.D.., has a huge social media following as Dr. Glaucomflecken, a character he created on Twitter when he was an ophthalmology resident in Iowa. More than 13,400 people have registered to attend the American Thoracic Society (ATS) International Conference, which is being held this weekend at the San Diego Convention Center.
Read More
